血清HE4、CA125检测及ROMA模型在卵巢癌诊断中的应用价值

发布时间：2018-02-01 17:53

本文关键词： 卵巢肿瘤人附睾分泌蛋白糖类抗原卵巢恶性肿瘤风险预测模型　出处：《重庆医学》2017年05期 　论文类型：期刊论文

【摘要】：目的探讨人附睾分泌蛋白4(HE4)、糖类抗原125(CA125)及卵巢恶性肿瘤风险预测模型(ROMA)在卵巢癌诊断中的应用价值。方法采用酶联免疫吸附试验及化学发光方法检测56例卵巢癌患者、73例卵巢良性肿瘤患者及50例健康对照者血清HE4及CA125水平,根据患者的绝经状况通过公式计算ROMA指数,绘制受试者工作特征(ROC)曲线并计算曲线下面积(AUC)。结果 HE4、CA125水平及ROMA指数在卵巢癌组分别为(345.33±605.03)pmol/L、(701.46±1 500.30)U/mL、(58.72±31.00)%,卵巢良性肿瘤组分别为(53.84±14.68)pmol/L、(44.25±45.81)U/mL、(10.80±6.75)%,健康对照组分别为(46.03±10.26)pmol/L、(17.39±10.64)U/mL、(6.92±3.85)%,卵巢癌组血清HE4、CA125水平及ROMA指数高于卵巢良性肿瘤组,差异有统计学意义(P0.05)。健康对照组和卵巢良性肿瘤组比较,HE4水平和ROMA指数差异无统计学意义(P0.05)。而CA125水平差异有统计学意义(P0.05)。血清HE4、CA125水平和ROMA指数对卵巢癌诊断的灵敏度分别为71.43%、76.79%、89.28%,特异度分别为93.15%、53.42%、94.52%,ROC-AUC分别为0.930、0.809、0.937,当对卵巢癌诊断的特异度为95.00%时,HE4、CA125和ROMA指数对卵巢癌诊断的灵敏度分别为80.40%、53.60%和83.90%。结论联合检测HE4和CA125计算ROMA指数对卵巢癌诊断灵敏度和特异度较高。
[Abstract]:Objective to study the expression of human epididymal secretory protein 4 (HE4). Carbohydrate antigen 125 (CA125) and its risk prediction model for ovarian malignancy. Methods Enzyme-linked immunosorbent assay (Elisa) and chemiluminescence assay were used to detect 56 patients with ovarian cancer. The serum levels of HE4 and CA125 in 73 patients with benign ovarian tumors and 50 healthy controls were calculated according to the menopausal status of the patients. The ROMA index was calculated by formula. The operating characteristics of subjects were drawn and the area under the curve was calculated. Results HE4. The CA125 level and ROMA index in ovarian cancer group were 345.33 卤605.03 mmol / L and 701.46 卤1 500.30 U / mL, respectively. 58.72 卤31.00 and 53.84 卤14.68 pmol / L, 44.25 卤45.81 U / mL of benign ovarian tumors, respectively. 10.80 卤6.75 渭 mL and 46.03 卤10.26 渭 mol / mL, 17.39 卤10.64 U / mL, respectively, in the healthy control group. The serum levels of HE4CA125 and ROMA index in ovarian cancer group were higher than those in benign ovarian tumor group (6.92 卤3.85). The difference was statistically significant (P 0.05). The comparison between healthy control group and benign ovarian tumor group. There was no significant difference between HE4 level and ROMA index (P 0.05), but there was significant difference in CA125 level (P 0.05). The sensitivity of CA125 level and ROMA index to the diagnosis of ovarian cancer were 71.43 and 76.799.28, and the specificity were 93.15% and 53.42%, respectively. 94.52 ROC-AUC were 0.930 ~ 0.809 ~ 0.937, respectively, and the specificity of diagnosis of ovarian cancer was 95.00. The sensitivity of CA125 and ROMA index for diagnosis of ovarian cancer was 80.40%, respectively. Conclusion the diagnostic sensitivity and specificity of ROMA index calculated by combined detection of HE4 and CA125 in ovarian cancer are high.
【作者单位】：南京医科大学附属无锡妇幼保健院妇科;
【分类号】：R737.31
【正文快照】： 卵巢癌是女性生殖系统三大常见恶性肿瘤之一,发病率仅次于子宫颈癌和子宫内膜癌,居第3位,但死亡率居第1位。糖类抗原125(cancer antigen 125,CA125)是目前临床上最常用于卵巢癌诊断的肿瘤标志物,但CA125水平升高并不仅限于卵巢恶性肿瘤中,在一些卵巢良性肿瘤、子宫内膜异位症

【相似文献】